Biomerica announces real-world results of its inFoods IBS product

Biomerica (BMRA), announced real-world results demonstrating the effectiveness of its inFoods IBS product, along with the launch of a proprietary real-time patient feedback system to enhance symptom tracking and improve patient outcomes. The initial analysis from more than 360 patients who enrolled in the real world inFoods IBS study revealed an average: 48.5% reduction in gastrointestinal pain; 49.8% reduction in bloating. This ongoing study tracks symptom reduction from a two-week baseline through an eight-week intervention, during which patients eliminate specific trigger foods identified using the InFoods IBS diagnostic system. These real-world outcomes align with-and in some cases exceed-results from prior randomized clinical trials conducted at leading U.S. medical centers. “We’re proud to share this real-world data that confirms the significant benefit inFoods IBS delivers to patients suffering from IBS,” said Zack Irani, CEO of Biomerica. “Our real-time symptom tracking platform gives physicians clinical insight throughout treatment, creating a personalized and dynamic approach to care.”